← Eichor
Condition: Janus Kinase Inhibitors Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Janus Kinase Inhibitors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK I
Phase 1/Phase 2 · 12 location(s) · iOnctura · NCT06887803A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Phase 1 · 5 location(s) · Prelude Therapeutics · NCT07469891Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease
Phase 2 · 1 location(s) · National Institute of Dental and Craniofacial Research (NIDC · NCT07281456The PODIUM Study - a Three-arm Comparison of Target Therapies After Anti-TNFα in Ulcerative Colitis
Phase N/A · 1 location(s) · Humanitas Clinical and Research Center · NCT06691061Vitiligo, New Treatment and Serum s100B
Phase 2/Phase 3 · 1 location(s) · South Valley University · NCT06768840Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata
Phase 3 · 18 location(s) · Sun Pharma Japan Limited · NCT07617597JAK Inhibition in Ulcerative Colitis
NA · 1 location(s) · Leiden University Medical Center · NCT05456412Effect of JAK Inhibitor on Erosion Healing in RA
Phase 4 · 1 location(s) · Chinese University of Hong Kong · NCT05955066Research Platform Myelofibrosis and Anemia
Phase N/A · 1 location(s) · iOMEDICO AG · NCT06976918A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With D
Phase N/A · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07487311Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Resp
Phase 3 · 215 location(s) · Kartos Therapeutics, Inc. · NCT06479135Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events
Phase 4 · 1 location(s) · Fundación de Investigación Biomédica - Hospital Universitari · NCT05313620REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases
Phase 4 · 7 location(s) · Sint Maartenskliniek · NCT07160231Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic E
EARLY_Phase 1 · 1 location(s) · Peng Zhang · NCT06119490A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.
Phase N/A · 30 location(s) · Pfizer · NCT05689151Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal
Phase 1/Phase 2 · 19 location(s) · Telios Pharma, Inc. · NCT05280509Ruxolitinib Treatment in Inclusion Body Myositis
Phase 2 · 21 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06536166Nerve Conduction Study for Assessment of Peripheral Neuropathy in Rheumatoid Arthritis Patients on the Janus Kinase Inhi
NA · 1 location(s) · Sohag University · NCT06977035Comparison of Oral Administration of a JAK Inhibitor in Rheumatoid Arthritis
Phase N/A · 1 location(s) · Centre Hospitalier Princesse Grace · NCT07674134Advanced Therapeutics in Rheumatoid Arthritis (RA)
Phase 4 · 1 location(s) · London Health Sciences Centre Research Institute OR Lawson R · NCT03976245Retifanlimab and Ruxolitinib In Solid Malignancies
Phase 1/Phase 2 · 1 location(s) · University of California, San Diego · NCT07219576A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Phase 2 · 70 location(s) · Karyopharm Therapeutics Inc · NCT05980806An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream
Phase N/A · 1 location(s) · Incyte Corporation · NCT06627335A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who
Phase 2 · 56 location(s) · Hoffmann-La Roche · NCT07137598ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07454226Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Phase 2 · 33 location(s) · GlaxoSmithKline · NCT06517875Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
Phase N/A · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06573593Amping up With PemJAK
Phase 2 · 1 location(s) · Seda S. Tolu · NCT07283822Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders
NA · 1 location(s) · prof. dr. Rik Schrijvers · NCT07261891A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial L
NA · 1 location(s) · China-Japan Friendship Hospital · NCT07406932
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.